PFIZER R&D UK LIMITED
Part of the multinational pharmaceutical group Pfizer, the company serves as a dedicated subsidiary for its UK-based research and development activities, including pharmaceutical sciences and clinical trial support.
Get an alert when PFIZER R&D UK LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£2.2M
+124.1% vs 2023
Net assets
£282M
+8.6% vs 2023
Employees
992
-21.8% vs 2023
Profit before tax
£15M
-30.5% vs 2023
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · Δ = latest vs prior filed period · latest reflected 2024-11-30
| Metric | Trend | 2023-11-30 | 2024-11-30 | Δ vs prior |
|---|---|---|---|---|
| Turnover | £273,325,000 | £347,005,000 | +27% | |
| Operating profit | £17,319,000 | £9,739,000 | -43.8% | |
| Profit before tax | £21,329,000 | £14,822,000 | -30.5% | |
| Net profit | £17,005,000 | £9,160,000 | -46.1% | |
| Cash | £964,000 | £2,160,000 | +124.1% | |
| Total assets less current liabilities | £274,682,000 | £294,857,000 | +7.3% | |
| Net assets | £259,250,000 | £281,560,000 | +8.6% | |
| Equity | £259,250,000 | £281,560,000 | +8.6% | |
| Average employees | 1,269 | 992 | -21.8% | |
| Wages | £102,777,000 | £96,396,000 | -6.2% | |
| Directors' remuneration | £1,422,000 | £245,000 | -82.8% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-11-30 | 2024-11-30 |
|---|---|---|---|
| Operating margin | 6.3% | 2.8% | |
| Net margin | 6.2% | 2.6% | |
| Return on capital employed | 6.3% | 3.3% | |
| Gearing (liabilities / total assets) | 23.5% | 20.9% | |
| Current ratio | 4.06x | 5.61x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- KPMG LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Based on these considerations, the directors believe that it remains appropriate to adopt the going concern basis of accounting in preparing the financial statements.”
Significant events
- “On 30th April 2024, Pfizer R&D UK Limited purchased the research and development business from fellow group undertaking Seagen U.K. Ltd. for £201,000. The book value of the net assets purchased was £nil. The excess consideration over the carrying value of the net assets acquired of £201,000 was recorded as a common control reserve.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
5 active · 10 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| HIGHTON, David Ian | Director | 2022-06-23 | Jul 1968 | British |
| LETBY, Joanne Theresa | Director | 2023-05-01 | Jan 1975 | British |
| MCGINLEY, John, Dr | Director | 2024-10-11 | Dec 1976 | Irish |
| PEARSON, Edwin James | Director | 2018-07-30 | Jan 1974 | British |
| SAINSBURY, Sarah Louise | Director | 2024-05-01 | Aug 1971 | British |
Show 10 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| MOUNT, Jacqui | Secretary | 2018-06-28 | 2021-01-21 |
| FRANKLIN, Ian Eric | Director | 2018-07-30 | 2021-02-09 |
| HARNETT, Denise Jean | Director | 2018-07-30 | 2024-05-01 |
| HENRY, Brian | Director | 2018-07-30 | 2023-07-14 |
| LEHMAN, David | Director | 2018-06-28 | 2023-05-01 |
| MOUNT, Jacqueline Ann | Director | 2021-02-08 | 2022-05-31 |
| NORDKAMP, Hendrikus Hermannus | Director | 2018-07-30 | 2019-05-15 |
| OSBORN, Benjamin | Director | 2018-11-20 | 2022-02-28 |
| RIENOW, Susan | Director | 2022-02-28 | 2024-10-08 |
| THOMPSON, Julian Keith, Dr | Director | 2018-06-28 | 2025-02-21 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Pfizer Inc | Corporate entity | Shares 75–100%, Voting 25–50%, Appoints directors (as trust) | 2018-11-30 | Active |
| Pfizer Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2018-06-28 | Ceased 2018-11-30 |
Filing timeline
Last 20 of 41 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-08-28 | AA | accounts | Accounts with accounts type full | |
| 2025-07-07 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-02-24 | TM01 | officers | Termination director company with name termination date | |
| 2024-10-14 | AP01 | officers | Appoint person director company with name date | |
| 2024-10-08 | TM01 | officers | Termination director company with name termination date | |
| 2024-09-02 | AA | accounts | Accounts with accounts type full | |
| 2024-07-10 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-05-10 | AP01 | officers | Appoint person director company with name date | |
| 2024-05-09 | TM01 | officers | Termination director company with name termination date | |
| 2023-08-22 | AA | accounts | Accounts with accounts type full | |
| 2023-07-18 | TM01 | officers | Termination director company with name termination date | |
| 2023-07-11 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-05-02 | TM01 | officers | Termination director company with name termination date | |
| 2023-05-02 | AP01 | officers | Appoint person director company with name date | |
| 2022-08-19 | AA | accounts | Accounts with accounts type full | |
| 2022-07-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-06-23 | AP01 | officers | Appoint person director company with name date | |
| 2022-05-31 | TM01 | officers | Termination director company with name termination date | |
| 2022-03-01 | AP01 | officers | Appoint person director company with name date | |
| 2022-03-01 | TM01 | officers | Termination director company with name termination date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.